-
1
-
-
84907573731
-
-
6th ed. Brussels, Belgium: International Diabetes Federation
-
International Diabetes Federation. IDF Diabetes Atlas. 6th ed. Brussels, Belgium: International Diabetes Federation; 2013.
-
(2013)
IDF Diabetes Atlas
-
-
-
2
-
-
21044443182
-
Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy
-
Yamagishi S, Imaizumi T. Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy. Curr Pharm Des. 2005;11:2279-99.
-
(2005)
Curr Pharm Des
, vol.11
, pp. 2279-2299
-
-
Yamagishi, S.1
Imaizumi, T.2
-
3
-
-
0035856980
-
Biochemistry and molecular cell biology of diabetic complications
-
Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001;414:813-80.
-
(2001)
Nature
, vol.414
, pp. 813-880
-
-
Brownlee, M.1
-
4
-
-
79952260576
-
Diabetes mellitus, fasting glucose, and risk of cause-specific death
-
Emerging Risk Factors Collaboration, Seshasai SR, Kaptoge S, Thompson A, Di Angelantonio E, Gao P, et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med. 2011;364:829-41.
-
(2011)
N Engl J Med
, vol.364
, pp. 829-841
-
-
Seshasai, S.R.1
Kaptoge, S.2
Thompson, A.3
Angelantonio, E.4
Gao, P.5
-
5
-
-
84866313972
-
Impact of diabetes mellitus on life expectancy and health-adjusted life expectancy in Canada
-
Loukine L, Waters C, Choi BC, Ellison J. Impact of diabetes mellitus on life expectancy and health-adjusted life expectancy in Canada. Popul Health Metr. 2012;10:7.
-
(2012)
Popul Health Metr
, vol.10
, pp. 7
-
-
Loukine, L.1
Waters, C.2
Choi, B.C.3
Ellison, J.4
-
6
-
-
84860514952
-
NIPPON DATA80 Research Group: Diabetes and life expectancy among Japanese - NIPPON DATA80
-
Turin TC, Murakami Y, Miura K, Rumana N, Kadota A, Ohkubo T, et al. NIPPON DATA80 Research Group: Diabetes and life expectancy among Japanese - NIPPON DATA80. Diabetes Res Clin Pract. 2012;96:e18-22.
-
(2012)
Diabetes Res Clin Pract
, vol.96
, pp. e18-22
-
-
Turin, T.C.1
Murakami, Y.2
Miura, K.3
Rumana, N.4
Kadota, A.5
Ohkubo, T.6
-
7
-
-
84858252996
-
Estimated morbidity and mortality in adolescents and young adults diagnosed with Type 2 diabetes mellitus
-
Rhodes ET, Prosser LA, Hoerger TJ, Lieu T, Ludwig DS, Laffel LM. Estimated morbidity and mortality in adolescents and young adults diagnosed with Type 2 diabetes mellitus. Diabet Med. 2012;29:453-63.
-
(2012)
Diabet Med
, vol.29
, pp. 453-463
-
-
Rhodes, E.T.1
Prosser, L.A.2
Hoerger, T.J.3
Lieu, T.4
Ludwig, D.S.5
Laffel, L.M.6
-
8
-
-
44449179863
-
Possible involvement of advanced glycation end-products (AGEs) in the pathogenesis of Alzheimer's disease
-
Takeuchi M, Yamagishi S. Possible involvement of advanced glycation end-products (AGEs) in the pathogenesis of Alzheimer's disease. Curr Pharm Des. 2008;14:973-8.
-
(2008)
Curr Pharm Des
, vol.14
, pp. 973-978
-
-
Takeuchi, M.1
Yamagishi, S.2
-
9
-
-
84855833476
-
Role of advanced glycation end products (AGEs) in osteoporosis in diabetes
-
Yamagishi S. Role of advanced glycation end products (AGEs) in osteoporosis in diabetes. Curr Drug Targets. 2011;12:2096-102.
-
(2011)
Curr Drug Targets
, vol.12
, pp. 2096-2102
-
-
Yamagishi, S.1
-
10
-
-
84906927578
-
Potential impact of dipeptidyl peptidase-4 inhibitors on cardiovascular pathophysiology in type 2 diabetes mellitus
-
Davidson MH. Potential impact of dipeptidyl peptidase-4 inhibitors on cardiovascular pathophysiology in type 2 diabetes mellitus. Postgrad Med. 2014;126:56-65.
-
(2014)
Postgrad Med
, vol.126
, pp. 56-65
-
-
Davidson, M.H.1
-
11
-
-
0034628425
-
Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy
-
The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med. 2000;342:381-9.
-
(2000)
N Engl J Med
, vol.342
, pp. 381-389
-
-
-
12
-
-
0142087597
-
Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study
-
Writing Team For The Diabetes Control And Complications Trial/Epidemiology Of Diabetes Interventions And Complications Research Group. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA. 2003;290:2159-67.
-
(2003)
JAMA
, vol.290
, pp. 2159-2167
-
-
-
13
-
-
84921917975
-
Effect of Intensive Diabetes Therapy on the Progression of Diabetic Retinopathy in Patients with Type 1 Diabetes: 18 Years of Follow-up in the DCCT/EDIC
-
The Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group. Effect of Intensive Diabetes Therapy on the Progression of Diabetic Retinopathy in Patients with Type 1 Diabetes: 18 Years of Follow-up in the DCCT/EDIC. Diabetes. 2014:doi: 10.2337/db14-0930.
-
(2014)
Diabetes
-
-
-
14
-
-
84922251694
-
Effect of intensive diabetes treatment on albuminuria in type 1 diabetes: long-term follow-up of the Diabetes Control and Complications Trial and Epidemiology of Diabetes Interventions and Complications study
-
DCCT/EDIC research group. Effect of intensive diabetes treatment on albuminuria in type 1 diabetes: long-term follow-up of the Diabetes Control and Complications Trial and Epidemiology of Diabetes Interventions and Complications study. Lancet Diab Endocrinol. 2014;2:793-800.
-
(2014)
Lancet Diab Endocrinol
, vol.2
, pp. 793-800
-
-
-
15
-
-
84892425163
-
DCCT/EDIC Research Group: Neuropathy and related findings in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study
-
Martin CL, Albers JW, Pop-Busui R. DCCT/EDIC Research Group: Neuropathy and related findings in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Diabetes Care. 2014;37:31-8.
-
(2014)
Diabetes Care
, vol.37
, pp. 31-38
-
-
Martin, C.L.1
Albers, J.W.2
Pop-Busui, R.3
-
16
-
-
0037986208
-
Diabetes Control and Complications Trial; Epidemiology of Diabetes Interventions and Complications Research Group: Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus
-
Nathan DM, Lachin J, Cleary P, Orchard T, Brillon DJ, Backlund JY, et al. Diabetes Control and Complications Trial; Epidemiology of Diabetes Interventions and Complications Research Group: Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. N Engl J Med. 2003;348:2294-303.
-
(2003)
N Engl J Med
, vol.348
, pp. 2294-2303
-
-
Nathan, D.M.1
Lachin, J.2
Cleary, P.3
Orchard, T.4
Brillon, D.J.5
Backlund, J.Y.6
-
17
-
-
29144453326
-
Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group: Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
-
Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, et al. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group: Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353:2643-53.
-
(2005)
N Engl J Med
, vol.353
, pp. 2643-2653
-
-
Nathan, D.M.1
Cleary, P.A.2
Backlund, J.Y.3
Genuth, S.M.4
Lachin, J.M.5
Orchard, T.J.6
-
18
-
-
84892408228
-
The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: overview
-
Nathan DM, DCCT/EDIC Research Group. The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: overview. Diabetes Care. 2014;37:9-16.
-
(2014)
Diabetes Care
, vol.37
, pp. 9-16
-
-
Nathan, D.M.1
-
19
-
-
84872303256
-
DCCT/EDIC Research Group: The effect of excess weight gain with intensive diabetes mellitus treatment on cardiovascular disease risk factors and atherosclerosis in type 1 diabetes mellitus: results from the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study (DCCT/EDIC) study
-
Purnell JQ, Zinman B, Brunzell JD. DCCT/EDIC Research Group: The effect of excess weight gain with intensive diabetes mellitus treatment on cardiovascular disease risk factors and atherosclerosis in type 1 diabetes mellitus: results from the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study (DCCT/EDIC) study. Circulation. 2013;127:180-7.
-
(2013)
Circulation
, vol.127
, pp. 180-187
-
-
Purnell, J.Q.1
Zinman, B.2
Brunzell, J.D.3
-
20
-
-
53749096863
-
10-year follow-up of intensive glucose control in type 2 diabetes
-
Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577-89.
-
(2008)
N Engl J Med
, vol.359
, pp. 1577-1589
-
-
Holman, R.R.1
Paul, S.K.2
Bethel, M.A.3
Matthews, D.R.4
Neil, H.A.5
-
21
-
-
0000358508
-
Activation of protein kinase C by elevation of glucose concentration: proposal for a mechanism in the development of diabetic vascular complications
-
Lee TS, Saltsman KA, Ohashi H, King GL. Activation of protein kinase C by elevation of glucose concentration: proposal for a mechanism in the development of diabetic vascular complications. Proc Natl Acad Sci U S A. 1989;86:5141-5.
-
(1989)
Proc Natl Acad Sci U S A
, vol.86
, pp. 5141-5145
-
-
Lee, T.S.1
Saltsman, K.A.2
Ohashi, H.3
King, G.L.4
-
22
-
-
0033868548
-
Effect of angiotensin II antagonist eprosartan on hyperglycemia-induced activation of intrarenal renin-angiotensin system in healthy humans
-
Osei SY, Price DA, Laffel LM, Lansang MC, Hollenberg NK. Effect of angiotensin II antagonist eprosartan on hyperglycemia-induced activation of intrarenal renin-angiotensin system in healthy humans. Hypertension. 2000;36:122-6.
-
(2000)
Hypertension
, vol.36
, pp. 122-126
-
-
Osei, S.Y.1
Price, D.A.2
Laffel, L.M.3
Lansang, M.C.4
Hollenberg, N.K.5
-
23
-
-
34247596394
-
Genetic deletion of p66(Shc) adaptor protein prevents hyperglycemia-induced endothelial dysfunction and oxidative stress
-
Camici GG, Schiavoni M, Francia P, Bachschmid M, Martin-Padura I, Hersberger M, et al. Genetic deletion of p66(Shc) adaptor protein prevents hyperglycemia-induced endothelial dysfunction and oxidative stress. Proc Natl Acad Sci U S A. 2007;104:5217-22.
-
(2007)
Proc Natl Acad Sci U S A
, vol.104
, pp. 5217-5222
-
-
Camici, G.G.1
Schiavoni, M.2
Francia, P.3
Bachschmid, M.4
Martin-Padura, I.5
Hersberger, M.6
-
24
-
-
42249097446
-
Final common molecular pathways of aging and cardiovascular disease: role of the p66Shc protein
-
Cosentino F, Francia P, Camici GG, Pelicci PG, Lüscher TF, Volpe M. Final common molecular pathways of aging and cardiovascular disease: role of the p66Shc protein. Arterioscler Thromb Vasc Biol. 2008;28:622-8.
-
(2008)
Arterioscler Thromb Vasc Biol
, vol.28
, pp. 622-628
-
-
Cosentino, F.1
Francia, P.2
Camici, G.G.3
Pelicci, P.G.4
Lüscher, T.F.5
Volpe, M.6
-
25
-
-
84920847396
-
Immunization with advanced glycation end products modified low density lipoprotein inhibits atherosclerosis progression in diabetic apoE and LDLR null mice
-
Zhu L, He Z, Wu F, Ding R, Jiang Q, Zhang J, et al. Immunization with advanced glycation end products modified low density lipoprotein inhibits atherosclerosis progression in diabetic apoE and LDLR null mice. Cardiovasc Diabetol. 2014;13:151.
-
(2014)
Cardiovasc Diabetol
, vol.13
, pp. 151
-
-
Zhu, L.1
He, Z.2
Wu, F.3
Ding, R.4
Jiang, Q.5
Zhang, J.6
-
26
-
-
84899490902
-
Advanced glycation endproducts trigger autophagy in cadiomyocyte via RAGE/PI3K/AKT/mTOR pathway
-
Hou X, Hu Z, Xu H, Xu J, Zhang S, Zhong Y, et al. Advanced glycation endproducts trigger autophagy in cadiomyocyte via RAGE/PI3K/AKT/mTOR pathway. Cardiovasc Diabetol. 2014;13:78.
-
(2014)
Cardiovasc Diabetol
, vol.13
, pp. 78
-
-
Hou, X.1
Hu, Z.2
Xu, H.3
Xu, J.4
Zhang, S.5
Zhong, Y.6
-
27
-
-
77953729130
-
Advanced glycation end products, oxidative stress and diabetic nephropathy
-
Yamagishi S, Matsui T. Advanced glycation end products, oxidative stress and diabetic nephropathy. Oxid Med Cell Longev. 2010;3:101-8.
-
(2010)
Oxid Med Cell Longev
, vol.3
, pp. 101-108
-
-
Yamagishi, S.1
Matsui, T.2
-
28
-
-
84903698784
-
Role of AGEs-RAGE system in cardiovascular disease
-
Fukami K, Yamagishi S, Okuda S. Role of AGEs-RAGE system in cardiovascular disease. Curr Pharm Des. 2014;20:2395-402.
-
(2014)
Curr Pharm Des
, vol.20
, pp. 2395-2402
-
-
Fukami, K.1
Yamagishi, S.2
Okuda, S.3
-
29
-
-
59749094860
-
Clinical review 2: The "metabolic memory": is more than just tight glucose control necessary to prevent diabetic complications?
-
Ceriello A, Ihnat MA, Thorpe JE. Clinical review 2: The "metabolic memory": is more than just tight glucose control necessary to prevent diabetic complications? J Clin Endocrinol Metab. 2009;94:410-5.
-
(2009)
J Clin Endocrinol Metab
, vol.94
, pp. 410-415
-
-
Ceriello, A.1
Ihnat, M.A.2
Thorpe, J.E.3
-
30
-
-
0036167208
-
Diabetes and advanced glycation endproducts
-
Vlassara H, Palace MR. Diabetes and advanced glycation endproducts. J Intern Med. 2002;251:87-101.
-
(2002)
J Intern Med
, vol.251
, pp. 87-101
-
-
Vlassara, H.1
Palace, M.R.2
-
31
-
-
84886235609
-
AGEs, rather than hyperglycemia, are responsible for microvascular complications in diabetes: a "glycoxidation-centric" point of view
-
Chilelli NC, Burlina S, Lapolla A. AGEs, rather than hyperglycemia, are responsible for microvascular complications in diabetes: a "glycoxidation-centric" point of view. Nutr Metab Cardiovasc Dis. 2013;23:913-9.
-
(2013)
Nutr Metab Cardiovasc Dis
, vol.23
, pp. 913-919
-
-
Chilelli, N.C.1
Burlina, S.2
Lapolla, A.3
-
32
-
-
0026452158
-
Hemoglobin-AGE: a circulating marker of advanced glycosylation
-
Makita Z, Vlassara H, Rayfield E, Cartwright K, Friedman E, Rodby R, et al. Hemoglobin-AGE: a circulating marker of advanced glycosylation. Science. 1992;258:651-3.
-
(1992)
Science
, vol.258
, pp. 651-653
-
-
Makita, Z.1
Vlassara, H.2
Rayfield, E.3
Cartwright, K.4
Friedman, E.5
Rodby, R.6
-
33
-
-
0030024095
-
Long-term assessment of glucose control by haemoglobin-AGE measurement
-
Wolffenbuttel BH, Giordano D, Founds HW, Bucala R. Long-term assessment of glucose control by haemoglobin-AGE measurement. Lancet. 1996;347:513-5.
-
(1996)
Lancet
, vol.347
, pp. 513-515
-
-
Wolffenbuttel, B.H.1
Giordano, D.2
Founds, H.W.3
Bucala, R.4
-
34
-
-
0030448322
-
Disparate changes in plasma and tissue pentosidine levels after kidney and kidney-pancreas transplantation
-
Hricik DE, Wu YC, Schulak A, Friedlander MA. Disparate changes in plasma and tissue pentosidine levels after kidney and kidney-pancreas transplantation. Clin Transplant. 1996;10:568-73.
-
(1996)
Clin Transplant
, vol.10
, pp. 568-573
-
-
Hricik, D.E.1
Wu, Y.C.2
Schulak, A.3
Friedlander, M.A.4
-
35
-
-
48249151077
-
Agents that block advanced glycation end product (AGE)-RAGE (receptor for AGEs)-oxidative stress system: a novel therapeutic strategy for diabetic vascular complications
-
Yamagishi S, Nakamura K, Matsui T, Ueda S, Fukami K, Okuda S. Agents that block advanced glycation end product (AGE)-RAGE (receptor for AGEs)-oxidative stress system: a novel therapeutic strategy for diabetic vascular complications. Expert Opin Investig Drugs. 2008;17:983-96.
-
(2008)
Expert Opin Investig Drugs
, vol.17
, pp. 983-996
-
-
Yamagishi, S.1
Nakamura, K.2
Matsui, T.3
Ueda, S.4
Fukami, K.5
Okuda, S.6
-
36
-
-
0037038819
-
Receptor for advanced glycation endproducts: a multiligand receptor magnifying cell stress in diverse pathologic settings
-
Stern D, Yan SD, Yan SF, Schmidt AM. Receptor for advanced glycation endproducts: a multiligand receptor magnifying cell stress in diverse pathologic settings. Adv Drug Deliv Rev. 2002;54:1615-25.
-
(2002)
Adv Drug Deliv Rev
, vol.54
, pp. 1615-1625
-
-
Stern, D.1
Yan, S.D.2
Yan, S.F.3
Schmidt, A.M.4
-
37
-
-
0032029363
-
AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus. I. The AGE concept
-
Bierhaus A, Hofmann MA, Ziegler R, Nawroth PP. AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus. I. The AGE concept. Cardiovasc Res. 1998;37:586-600.
-
(1998)
Cardiovasc Res
, vol.37
, pp. 586-600
-
-
Bierhaus, A.1
Hofmann, M.A.2
Ziegler, R.3
Nawroth, P.P.4
-
38
-
-
42049109529
-
Receptor for advanced glycation end products (RAGE): a novel therapeutic target for diabetic vascular complication
-
Yamagishi S, Nakamura K, Matsui T, Noda Y, Imaizumi T. Receptor for advanced glycation end products (RAGE): a novel therapeutic target for diabetic vascular complication. Curr Pharm Des. 2008;14:487-95.
-
(2008)
Curr Pharm Des
, vol.14
, pp. 487-495
-
-
Yamagishi, S.1
Nakamura, K.2
Matsui, T.3
Noda, Y.4
Imaizumi, T.5
-
39
-
-
84885955952
-
Targeting advanced glycation endproducts and mitochondrial dysfunction in cardiovascular disease
-
Ward MS, Fortheringham AK, Cooper ME, Forbes JM. Targeting advanced glycation endproducts and mitochondrial dysfunction in cardiovascular disease. Curr Opin Pharmacol. 2013;13:654-61.
-
(2013)
Curr Opin Pharmacol
, vol.13
, pp. 654-661
-
-
Ward, M.S.1
Fortheringham, A.K.2
Cooper, M.E.3
Forbes, J.M.4
-
40
-
-
84899763405
-
Diabetes, aging, and their tissue complications
-
Bucala R. Diabetes, aging, and their tissue complications. J Clin Invest. 2014;124:1887-8.
-
(2014)
J Clin Invest
, vol.124
, pp. 1887-1888
-
-
Bucala, R.1
-
41
-
-
0035656173
-
Diabetes-associated sustained activation of the transcription factor nuclear factor-kappaB
-
Bierhaus A, Schiekofer S, Schwaninger M, Andrassy M, Humpert PM, Chen J, et al. Diabetes-associated sustained activation of the transcription factor nuclear factor-kappaB. Diabetes. 2001;50:2792-808.
-
(2001)
Diabetes
, vol.50
, pp. 2792-2808
-
-
Bierhaus, A.1
Schiekofer, S.2
Schwaninger, M.3
Andrassy, M.4
Humpert, P.M.5
Chen, J.6
-
42
-
-
33746019939
-
Pigment epithelium-derived factor inhibits advanced glycation end product-induced retinal vascular hyperpermeability by blocking reactive oxygen species-mediated vascular endothelial growth factor expression
-
Yamagishi S, Nakamura K, Matsui T, Inagaki Y, Takenaka K, Jinnouchi Y, et al. Pigment epithelium-derived factor inhibits advanced glycation end product-induced retinal vascular hyperpermeability by blocking reactive oxygen species-mediated vascular endothelial growth factor expression. J Biol Chem. 2006;281:20213-20.
-
(2006)
J Biol Chem
, vol.281
, pp. 20213-20220
-
-
Yamagishi, S.1
Nakamura, K.2
Matsui, T.3
Inagaki, Y.4
Takenaka, K.5
Jinnouchi, Y.6
-
43
-
-
77955414324
-
Pigment epithelium-derived factor inhibits advanced glycation end product-elicited mesangial cell damage by blocking NF-kappaB activation
-
Ide Y, Matsui T, Ishibashi Y, Takeuchi M, Yamagishi S. Pigment epithelium-derived factor inhibits advanced glycation end product-elicited mesangial cell damage by blocking NF-kappaB activation. Microvasc Res. 2010;80:227-32.
-
(2010)
Microvasc Res
, vol.80
, pp. 227-232
-
-
Ide, Y.1
Matsui, T.2
Ishibashi, Y.3
Takeuchi, M.4
Yamagishi, S.5
-
45
-
-
37349025554
-
Olmesartan blocks inflammatory reactions in endothelial cells evoked by advanced glycation end products by suppressing generation of reactive oxygen species
-
Yamagishi S, Matsui T, Nakamura K, Inoue H, Takeuchi M, Ueda S, et al. Olmesartan blocks inflammatory reactions in endothelial cells evoked by advanced glycation end products by suppressing generation of reactive oxygen species. Ophthalmic Res. 2008;40:10-5.
-
(2008)
Ophthalmic Res
, vol.40
, pp. 10-15
-
-
Yamagishi, S.1
Matsui, T.2
Nakamura, K.3
Inoue, H.4
Takeuchi, M.5
Ueda, S.6
-
46
-
-
84921967720
-
Yamagishi: Sulforaphane inhibits advanced glycation end product-induced pericyte damage by reducing expression of receptor for advanced glycation end products
-
Maeda S, Matsui T, Ojima A, Takeuchi M. Yamagishi: Sulforaphane inhibits advanced glycation end product-induced pericyte damage by reducing expression of receptor for advanced glycation end products. Nutr Res. 2014;34:807-13.
-
(2014)
Nutr Res
, vol.34
, pp. 807-813
-
-
Maeda, S.1
Matsui, T.2
Ojima, A.3
Takeuchi, M.4
-
47
-
-
84883084459
-
Advanced glycation end products evoke endothelial cell damage by stimulating soluble dipeptidyl peptidase-4 production and its interaction with mannose 6-phosphate/insulin-like growth factor II receptor
-
Ishibashi Y, Matsui T, Maeda S, Higashimoto Y, Yamagishi S. Advanced glycation end products evoke endothelial cell damage by stimulating soluble dipeptidyl peptidase-4 production and its interaction with mannose 6-phosphate/insulin-like growth factor II receptor. Cardiovasc Diabetol. 2013;12:125.
-
(2013)
Cardiovasc Diabetol
, vol.12
, pp. 125
-
-
Ishibashi, Y.1
Matsui, T.2
Maeda, S.3
Higashimoto, Y.4
Yamagishi, S.5
-
48
-
-
84899572841
-
Advanced glycation end products potentiate citrated plasma-evoked oxidative and inflammatory reactions in endothelial cells by up-regulating protease-activated receptor-1 expression
-
Ishibashi Y, Matsui T, Ueda S, Fukami K, Yamagishi S. Advanced glycation end products potentiate citrated plasma-evoked oxidative and inflammatory reactions in endothelial cells by up-regulating protease-activated receptor-1 expression. Cardiovasc Diabetol. 2014;13:60.
-
(2014)
Cardiovasc Diabetol
, vol.13
, pp. 60
-
-
Ishibashi, Y.1
Matsui, T.2
Ueda, S.3
Fukami, K.4
Yamagishi, S.5
-
49
-
-
35748972367
-
Food-derived advanced glycation end products (AGEs): a novel therapeutic target for various disorders
-
Yamagishi S, Ueda S, Okuda S. Food-derived advanced glycation end products (AGEs): a novel therapeutic target for various disorders. Curr Pharm Des. 2007;13:2832-6.
-
(2007)
Curr Pharm Des
, vol.13
, pp. 2832-2836
-
-
Yamagishi, S.1
Ueda, S.2
Okuda, S.3
-
50
-
-
42549089560
-
Advanced glycation end product homeostasis: exogenous oxidants and innate defenses
-
Vlassara H, Uribarri J, Cai W, Striker G. Advanced glycation end product homeostasis: exogenous oxidants and innate defenses. Ann N Y Acad Sci. 2008;1126:46-52.
-
(2008)
Ann N Y Acad Sci
, vol.1126
, pp. 46-52
-
-
Vlassara, H.1
Uribarri, J.2
Cai, W.3
Striker, G.4
-
51
-
-
84896736034
-
Advanced glycation end products (AGE) and diabetes: cause, effect, or both?
-
Vlassara H, Uribarri J. Advanced glycation end products (AGE) and diabetes: cause, effect, or both? Curr Diab Rep. 2014;14:453.
-
(2014)
Curr Diab Rep
, vol.14
, pp. 453
-
-
Vlassara, H.1
Uribarri, J.2
-
52
-
-
84913606113
-
Effect of advanced glycation end product intake on inflammation and aging: a systematic review
-
Van Puyvelde K, Mets T, Njemini R, Beyer I, Bautmans I. Effect of advanced glycation end product intake on inflammation and aging: a systematic review. Nutr Rev. 2014;72:638-50.
-
(2014)
Nutr Rev
, vol.72
, pp. 638-650
-
-
Puyvelde, K.1
Mets, T.2
Njemini, R.3
Beyer, I.4
Bautmans, I.5
-
53
-
-
45649085142
-
Possible involvement of tobacco-derived advanced glycation end products (AGEs) in an increased risk for developing cancers and cardiovascular disease in former smokers
-
Yamagishi S, Matsui T, Nakamura K. Possible involvement of tobacco-derived advanced glycation end products (AGEs) in an increased risk for developing cancers and cardiovascular disease in former smokers. Med Hypotheses. 2008;71:259-61.
-
(2008)
Med Hypotheses
, vol.71
, pp. 259-261
-
-
Yamagishi, S.1
Matsui, T.2
Nakamura, K.3
-
54
-
-
80052142793
-
Restriction of advanced glycation end products improves insulin resistance in human type 2 diabetes: potential role of AGER1 and SIRT1
-
Uribarri J, Cai W, Ramdas M, Goodman S, Pyzik R, Chen X, et al. Restriction of advanced glycation end products improves insulin resistance in human type 2 diabetes: potential role of AGER1 and SIRT1. Diabetes Care. 2011;34:1610-6.
-
(2011)
Diabetes Care
, vol.34
, pp. 1610-1616
-
-
Uribarri, J.1
Cai, W.2
Ramdas, M.3
Goodman, S.4
Pyzik, R.5
Chen, X.6
-
55
-
-
80052059557
-
AGE restriction in diabetes mellitus: a paradigm shift
-
Vlassara H, Striker GE. AGE restriction in diabetes mellitus: a paradigm shift. Nat Rev Endocrinol. 2011;7:526-39.
-
(2011)
Nat Rev Endocrinol
, vol.7
, pp. 526-539
-
-
Vlassara, H.1
Striker, G.E.2
-
56
-
-
48749126012
-
Oral glycotoxins determine the effects of calorie restriction on oxidant stress, age-related diseases, and lifespan
-
Cai W, He JC, Zhu L, Chen X, Zheng F, Striker GE, et al. Oral glycotoxins determine the effects of calorie restriction on oxidant stress, age-related diseases, and lifespan. Am J Pathol. 2008;173:327-36.
-
(2008)
Am J Pathol
, vol.173
, pp. 327-336
-
-
Cai, W.1
He, J.C.2
Zhu, L.3
Chen, X.4
Zheng, F.5
Striker, G.E.6
-
57
-
-
58149090676
-
The role of incretins in glucose homeostasis and diabetes treatment
-
Kim W, Egan JM. The role of incretins in glucose homeostasis and diabetes treatment. Pharmacol Rev. 2008;60:470-512.
-
(2008)
Pharmacol Rev
, vol.60
, pp. 470-512
-
-
Kim, W.1
Egan, J.M.2
-
58
-
-
84861322287
-
Pleiotropic effects of glucagon-like peptide-1 (GLP-1)-based therapies on vascular complications in diabetes
-
Yamagishi S, Matsui T. Pleiotropic effects of glucagon-like peptide-1 (GLP-1)-based therapies on vascular complications in diabetes. Curr Pharm Des. 2011;17:4379-85.
-
(2011)
Curr Pharm Des
, vol.17
, pp. 4379-4385
-
-
Yamagishi, S.1
Matsui, T.2
-
59
-
-
70349774693
-
On the origin of serum CD26 and its altered concentration in cancer patients
-
Cordero OJ, Salgado FJ, Nogueira M. On the origin of serum CD26 and its altered concentration in cancer patients. Cancer Immunol Immunother. 2009;58:1723-47.
-
(2009)
Cancer Immunol Immunother
, vol.58
, pp. 1723-1747
-
-
Cordero, O.J.1
Salgado, F.J.2
Nogueira, M.3
-
60
-
-
70350328161
-
Dipeptidyl peptidase inhibitors, an emerging drug class for inflammatory disease?
-
Yazbeck R, Howarth GS, Abbott CA. Dipeptidyl peptidase inhibitors, an emerging drug class for inflammatory disease? Trends Pharmacol Sci. 2009;30:600-7.
-
(2009)
Trends Pharmacol Sci
, vol.30
, pp. 600-607
-
-
Yazbeck, R.1
Howarth, G.S.2
Abbott, C.A.3
-
61
-
-
0036068322
-
Inhibition of gastric inhibitory polypeptide signaling prevents obesity
-
Miyawaki K, Yamada Y, Ban N, Ihara Y, Tsukiyama K, Zhou H, et al. Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nat Med. 2002;8:738-42.
-
(2002)
Nat Med
, vol.8
, pp. 738-742
-
-
Miyawaki, K.1
Yamada, Y.2
Ban, N.3
Ihara, Y.4
Tsukiyama, K.5
Zhou, H.6
-
62
-
-
36148996843
-
G-protein-coupled receptors and islet function-implications for treatment of type 2 diabetes
-
Winzell MS, Ahrén B. G-protein-coupled receptors and islet function-implications for treatment of type 2 diabetes. Pharmacol Rev. 2007;116:437-48.
-
(2007)
Pharmacol Rev
, vol.116
, pp. 437-448
-
-
Winzell, M.S.1
Ahrén, B.2
-
63
-
-
78650733949
-
Cardiovascular comorbidities of type 2 diabetes mellitus: defining the potential of glucagonlike peptide-1-based therapies
-
Chilton R, Wyatt J, Nandish S, Oliveros R, Lujan M. Cardiovascular comorbidities of type 2 diabetes mellitus: defining the potential of glucagonlike peptide-1-based therapies. Am J Med. 2011;124(1 Suppl):S35-53.
-
(2011)
Am J Med
, vol.124
, Issue.1
, pp. S35-53
-
-
Chilton, R.1
Wyatt, J.2
Nandish, S.3
Oliveros, R.4
Lujan, M.5
-
64
-
-
84906079407
-
Pleiotropic effects of the dipeptidylpeptidase-4 inhibitors on the cardiovascular system
-
Aroor AR, Sowers JR, Jia G, DeMarco VG. Pleiotropic effects of the dipeptidylpeptidase-4 inhibitors on the cardiovascular system. Am J Physiol Heart Circ Physiol. 2014;307:H477-92.
-
(2014)
Am J Physiol Heart Circ Physiol
, vol.307
, pp. H477-H492
-
-
Aroor, A.R.1
Sowers, J.R.2
Jia, G.3
DeMarco, V.G.4
-
65
-
-
84926197236
-
The potential for renoprotection with incretin-based drugs
-
Tanaka T, Higashijima Y, Wada T, Nangaku M. The potential for renoprotection with incretin-based drugs. Kidney Int. 2014;86:701-11.
-
(2014)
Kidney Int
, vol.86
, pp. 701-711
-
-
Tanaka, T.1
Higashijima, Y.2
Wada, T.3
Nangaku, M.4
-
66
-
-
0034843965
-
Endothelial apoptosis: biochemical characteristics and potential implications for atherosclerosis
-
Choy JC, Granville DJ, Hunt DW, McManus BM. Endothelial apoptosis: biochemical characteristics and potential implications for atherosclerosis. J Mol Cell Cardiol. 2001;33:1673-90.
-
(2001)
J Mol Cell Cardiol
, vol.33
, pp. 1673-1690
-
-
Choy, J.C.1
Granville, D.J.2
Hunt, D.W.3
McManus, B.M.4
-
67
-
-
33646081531
-
Hepatocyte growth factor protects human endothelial cells against advanced glycation end products-induced apoptosis
-
Zhou YJ, Wang JH, Zhang J. Hepatocyte growth factor protects human endothelial cells against advanced glycation end products-induced apoptosis. Biochem Biophys Res Commun. 2006;344:658-66.
-
(2006)
Biochem Biophys Res Commun
, vol.344
, pp. 658-666
-
-
Zhou, Y.J.1
Wang, J.H.2
Zhang, J.3
-
68
-
-
39049113549
-
Role of oxidative stress in the development of vascular injury and its therapeutic intervention by nifedipine
-
Yamagishi S, Nakamura K, Matsui T. Role of oxidative stress in the development of vascular injury and its therapeutic intervention by nifedipine. Curr Med Chem. 2008;15:172-7.
-
(2008)
Curr Med Chem
, vol.15
, pp. 172-177
-
-
Yamagishi, S.1
Nakamura, K.2
Matsui, T.3
-
69
-
-
84898906334
-
LR-90 prevents methylglyoxal-induced oxidative stress and apoptosis in human endothelial cells
-
Figarola JL, Singhal J, Rahbar S, Awasthi S, Singhal SS. LR-90 prevents methylglyoxal-induced oxidative stress and apoptosis in human endothelial cells. Apoptosis. 2014;19:776-88.
-
(2014)
Apoptosis
, vol.19
, pp. 776-788
-
-
Figarola, J.L.1
Singhal, J.2
Rahbar, S.3
Awasthi, S.4
Singhal, S.S.5
-
70
-
-
59249107409
-
Decreased vascular repair and neovascularization with ageing: mechanisms and clinical relevance with an emphasis on hypoxia-inducible factor-1
-
Hoenig MR, Bianchi C, Rosenzweig A, Sellke FW. Decreased vascular repair and neovascularization with ageing: mechanisms and clinical relevance with an emphasis on hypoxia-inducible factor-1. Curr Mol Med. 2008;8:754-67.
-
(2008)
Curr Mol Med
, vol.8
, pp. 754-767
-
-
Hoenig, M.R.1
Bianchi, C.2
Rosenzweig, A.3
Sellke, F.W.4
-
71
-
-
61849161661
-
Advanced glycation end products impair function of late endothelial progenitor cells through effects on protein kinase Akt and cyclooxygenase-2
-
Chen Q, Dong L, Wang L, Kang L, Xu B. Advanced glycation end products impair function of late endothelial progenitor cells through effects on protein kinase Akt and cyclooxygenase-2. Biochem Biophys Res Commun. 2009;381:192-7.
-
(2009)
Biochem Biophys Res Commun
, vol.381
, pp. 192-197
-
-
Chen, Q.1
Dong, L.2
Wang, L.3
Kang, L.4
Xu, B.5
-
72
-
-
33646769652
-
Depression of progenitor cell function by advanced glycation endproducts (AGEs): potential relevance for impaired angiogenesis in advanced age and diabetes
-
Scheubel RJ, Kahrstedt S, Weber H, Holtz J, Friedrich I, Borgermann J, et al. Depression of progenitor cell function by advanced glycation endproducts (AGEs): potential relevance for impaired angiogenesis in advanced age and diabetes. Exp Gerontol. 2006;41:540-8.
-
(2006)
Exp Gerontol
, vol.41
, pp. 540-548
-
-
Scheubel, R.J.1
Kahrstedt, S.2
Weber, H.3
Holtz, J.4
Friedrich, I.5
Borgermann, J.6
-
73
-
-
41949108995
-
Advanced glycation of fibronectin impairs vascular repair by endothelial progenitor cells: implications for vasodegeneration in diabetic retinopathy
-
Bhatwadekar AD, Glenn JV, Li G, Curtis TM, Gardiner TA, Stitt AW. Advanced glycation of fibronectin impairs vascular repair by endothelial progenitor cells: implications for vasodegeneration in diabetic retinopathy. Invest Ophthalmol Vis Sci. 2008;49:1232-41.
-
(2008)
Invest Ophthalmol Vis Sci
, vol.49
, pp. 1232-1241
-
-
Bhatwadekar, A.D.1
Glenn, J.V.2
Li, G.3
Curtis, T.M.4
Gardiner, T.A.5
Stitt, A.W.6
-
74
-
-
84863499980
-
Imaizumi: Serum levels of advanced glycation end products (AGEs) are inversely associated with the number and migratory activity of circulating endothelial progenitor cells in apparently healthy subjects
-
Ueda S, Yamagishi S, Matsui T, Noda Y, Ueda S, Jinnouchi Y, et al. Imaizumi: Serum levels of advanced glycation end products (AGEs) are inversely associated with the number and migratory activity of circulating endothelial progenitor cells in apparently healthy subjects. Cardiovasc Ther. 2012;30:249-54.
-
(2012)
Cardiovasc Ther
, vol.30
, pp. 249-254
-
-
Ueda, S.1
Yamagishi, S.2
Matsui, T.3
Noda, Y.4
Ueda, S.5
Jinnouchi, Y.6
-
75
-
-
79952985492
-
Advanced glycation end products, carotid atherosclerosis, and circulating endothelial progenitor cells in patients with end-stage renal disease
-
Ueno H, Koyama H, Fukumoto S, Tanaka S, Shoji T, Shoji T, et al. Advanced glycation end products, carotid atherosclerosis, and circulating endothelial progenitor cells in patients with end-stage renal disease. Metabolism. 2011;60:453-9.
-
(2011)
Metabolism
, vol.60
, pp. 453-459
-
-
Ueno, H.1
Koyama, H.2
Fukumoto, S.3
Tanaka, S.4
Shoji, T.5
Shoji, T.6
-
76
-
-
84863787414
-
Glucagon-like peptide-1 (GLP-1) protects vascular endothelial cells against advanced glycation end products (AGEs)-induced apoptosis
-
BR286-91
-
Zhan Y, Sun HL, Chen H, Zhang H, Sun J, Zhang Z, et al. Glucagon-like peptide-1 (GLP-1) protects vascular endothelial cells against advanced glycation end products (AGEs)-induced apoptosis. Med Sci Monit. 2012;18:BR286-91.
-
(2012)
Med Sci Monit
, vol.18
-
-
Zhan, Y.1
Sun, H.L.2
Chen, H.3
Zhang, H.4
Sun, J.5
Zhang, Z.6
-
77
-
-
77953959949
-
Glucagon-like peptide 1 prevents reactive oxygen species-induced endothelial cell senescence through the activation of protein kinase A
-
Oeseburg H, de Boer RA, Buikema H, van der Harst P, van Gilst WH, Silljé HH. Glucagon-like peptide 1 prevents reactive oxygen species-induced endothelial cell senescence through the activation of protein kinase A. Arterioscler Thromb Vasc Biol. 2010;30:1407-14.
-
(2010)
Arterioscler Thromb Vasc Biol
, vol.30
, pp. 1407-1414
-
-
Oeseburg, H.1
Boer, R.A.2
Buikema, H.3
Harst, P.4
Gilst, W.H.5
Silljé, H.H.6
-
78
-
-
77958195997
-
The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes: possible role of stromal-derived factor-1alpha
-
Fadini GP, Boscaro E, Albiero M, Menegazzo L, Frison V, de Kreutzenberg S, et al. The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes: possible role of stromal-derived factor-1alpha. Diabetes Care. 2010;33:1607-9.
-
(2010)
Diabetes Care
, vol.33
, pp. 1607-1609
-
-
Fadini, G.P.1
Boscaro, E.2
Albiero, M.3
Menegazzo, L.4
Frison, V.5
Kreutzenberg, S.6
-
79
-
-
84924288178
-
Cytokine biomarkers, endothelial inflammation, and atherosclerosis in the metabolic syndrome: emerging concepts
-
Rizvi AA. Cytokine biomarkers, endothelial inflammation, and atherosclerosis in the metabolic syndrome: emerging concepts. Am J Med Sci. 2009;55:659-65.
-
(2009)
Am J Med Sci
, vol.55
, pp. 659-665
-
-
Rizvi, A.A.1
-
80
-
-
55349145657
-
Inflammation at the molecular interface of atherogenesis: an anthropological journey
-
Lamon BD, Hajjar DP. Inflammation at the molecular interface of atherogenesis: an anthropological journey. Am J Pathol. 2008;173:1253-64.
-
(2008)
Am J Pathol
, vol.173
, pp. 1253-1264
-
-
Lamon, B.D.1
Hajjar, D.P.2
-
81
-
-
84869848893
-
Positive association between serum level of glyceraldehyde-derived advanced glycation end products and vascular inflammation evaluated by [(18)F]fluorodeoxyglucose positron emission tomography
-
Tahara N, Yamagishi S, Takeuchi M, Honda A, Tahara A, Nitta Y, et al. Positive association between serum level of glyceraldehyde-derived advanced glycation end products and vascular inflammation evaluated by [(18)F]fluorodeoxyglucose positron emission tomography. Diabetes Care. 2012;35:2618-25.
-
(2012)
Diabetes Care
, vol.35
, pp. 2618-2625
-
-
Tahara, N.1
Yamagishi, S.2
Takeuchi, M.3
Honda, A.4
Tahara, A.5
Nitta, Y.6
-
82
-
-
84903708769
-
Molecular imaging of vascular inflammation
-
Tahara N, Tahara A, Honda A, Nitta Y, Kodama N, Yamagishi S, et al. Molecular imaging of vascular inflammation. Curr Pharm Des. 2014;20:2439-47.
-
(2014)
Curr Pharm Des
, vol.20
, pp. 2439-2447
-
-
Tahara, N.1
Tahara, A.2
Honda, A.3
Nitta, Y.4
Kodama, N.5
Yamagishi, S.6
-
83
-
-
0025980167
-
Atherosclerotic plaque caps are locally weakened when macrophages density is increased
-
Lendon CL, Davies MJ, Born GV, Richardson PD. Atherosclerotic plaque caps are locally weakened when macrophages density is increased. Atherosclerosis. 1991;87:87-90.
-
(1991)
Atherosclerosis
, vol.87
, pp. 87-90
-
-
Lendon, C.L.1
Davies, M.J.2
Born, G.V.3
Richardson, P.D.4
-
84
-
-
58549099453
-
Inflammation and plaque vulnerability
-
Shak PK. Inflammation and plaque vulnerability. Cardiovasc Drugs Ther. 2009;23:31-40.
-
(2009)
Cardiovasc Drugs Ther
, vol.23
, pp. 31-40
-
-
Shak, P.K.1
-
85
-
-
57549112353
-
Metalloproteinase expression in monocytes and macrophages and its relationship to atherosclerotic plaque instability
-
Newby AC. Metalloproteinase expression in monocytes and macrophages and its relationship to atherosclerotic plaque instability. Arterioscler Thromb Vasc Biol. 2008;28:2108-14.
-
(2008)
Arterioscler Thromb Vasc Biol
, vol.28
, pp. 2108-2114
-
-
Newby, A.C.1
-
86
-
-
0032134003
-
Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice
-
Gu L, Okada Y, Clinton SK, Gerard C, Sukhova GK, Libby P, et al. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol Cell. 1998;2:275-81.
-
(1998)
Mol Cell
, vol.2
, pp. 275-281
-
-
Gu, L.1
Okada, Y.2
Clinton, S.K.3
Gerard, C.4
Sukhova, G.K.5
Libby, P.6
-
87
-
-
0032572719
-
Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis
-
Boring L, Gosling J, Cleary M, Charo IF. Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature. 1998;394:894-7.
-
(1998)
Nature
, vol.394
, pp. 894-897
-
-
Boring, L.1
Gosling, J.2
Cleary, M.3
Charo, I.F.4
-
88
-
-
66949136652
-
ICAM-1 signaling in endothelial cells
-
Lawson C, Wolf S. ICAM-1 signaling in endothelial cells. Pharmacol Rep. 2009;61:22-32.
-
(2009)
Pharmacol Rep
, vol.61
, pp. 22-32
-
-
Lawson, C.1
Wolf, S.2
-
89
-
-
33947354929
-
Vascular cell adhesion molecule-1: a viable therapeutic target for atherosclerosis?
-
Preiss DJ, Sattar N. Vascular cell adhesion molecule-1: a viable therapeutic target for atherosclerosis? Int J Clin Pract. 2007;6:697-701.
-
(2007)
Int J Clin Pract
, vol.6
, pp. 697-701
-
-
Preiss, D.J.1
Sattar, N.2
-
90
-
-
84887987862
-
Pigment epithelium-derived factor (PEDF) binds to caveolin-1 and inhibits the pro-inflammatory effects of caveolin-1 in endothelial cells
-
Matsui T, Higashimoto Y, Taira J, Yamagishi S. Pigment epithelium-derived factor (PEDF) binds to caveolin-1 and inhibits the pro-inflammatory effects of caveolin-1 in endothelial cells. Biochem Biophys Res Commun. 2013;441:405-10.
-
(2013)
Biochem Biophys Res Commun
, vol.441
, pp. 405-410
-
-
Matsui, T.1
Higashimoto, Y.2
Taira, J.3
Yamagishi, S.4
-
91
-
-
33645890286
-
Role of advanced glycation end products (AGEs) in thrombogenic abnormalities in diabetes
-
Takenaka K, Yamagishi S, Matsui T, Nakamura K, Imaizumi T. Role of advanced glycation end products (AGEs) in thrombogenic abnormalities in diabetes. Curr Neurovasc Res. 2006;3:73-7.
-
(2006)
Curr Neurovasc Res
, vol.3
, pp. 73-77
-
-
Takenaka, K.1
Yamagishi, S.2
Matsui, T.3
Nakamura, K.4
Imaizumi, T.5
-
92
-
-
0031773362
-
Advanced glycation endproducts inhibit prostacyclin production and induce plasminogen activator inhibitor-1 in human microvascular endothelial cells
-
Yamagishi S, Fujimori H, Yonekura H, Yamamoto Y, Yamamoto H. Advanced glycation endproducts inhibit prostacyclin production and induce plasminogen activator inhibitor-1 in human microvascular endothelial cells. Diabetologia. 1998;41:1435-41.
-
(1998)
Diabetologia
, vol.41
, pp. 1435-1441
-
-
Yamagishi, S.1
Fujimori, H.2
Yonekura, H.3
Yamamoto, Y.4
Yamamoto, H.5
-
93
-
-
73949118948
-
Glucagon-like peptide-1 (GLP-1) inhibits advanced glycation end product (AGE)-induced up-regulation of VCAM-1 mRNA levels in endothelial cells by suppressing AGE receptor (RAGE) expression
-
Ishibashi Y, Matsui T, Takeuchi M, Yamagishi S. Glucagon-like peptide-1 (GLP-1) inhibits advanced glycation end product (AGE)-induced up-regulation of VCAM-1 mRNA levels in endothelial cells by suppressing AGE receptor (RAGE) expression. Biochem Biophys Res Commun. 2010;391:1405-8.
-
(2010)
Biochem Biophys Res Commun
, vol.391
, pp. 1405-1408
-
-
Ishibashi, Y.1
Matsui, T.2
Takeuchi, M.3
Yamagishi, S.4
-
94
-
-
84862209599
-
Glucose-dependent insulinotropic polypeptide (GIP) inhibits signaling pathways of advanced glycation end products (AGEs) in endothelial cells via its antioxidative properties
-
Ojima A, Matsui T, Maeda S, Takeuchi M, Yamagishi S. Glucose-dependent insulinotropic polypeptide (GIP) inhibits signaling pathways of advanced glycation end products (AGEs) in endothelial cells via its antioxidative properties. Horm Metab Res. 2012;44:501-5.
-
(2012)
Horm Metab Res
, vol.44
, pp. 501-505
-
-
Ojima, A.1
Matsui, T.2
Maeda, S.3
Takeuchi, M.4
Yamagishi, S.5
-
95
-
-
79955480528
-
Vildagliptin blocks vascular injury in thoracic aorta of diabetic rats by suppressing advanced glycation end product-receptor axis
-
Matsui T, Nishino Y, Takeuchi M, Yamagishi S. Vildagliptin blocks vascular injury in thoracic aorta of diabetic rats by suppressing advanced glycation end product-receptor axis. Pharmacol Res. 2011;63:383-8.
-
(2011)
Pharmacol Res
, vol.63
, pp. 383-388
-
-
Matsui, T.1
Nishino, Y.2
Takeuchi, M.3
Yamagishi, S.4
-
96
-
-
84862027177
-
Vildagliptin inhibits oxidative stress and vascular damage in streptozotocin-induced diabetic rats
-
Maeda S, Matsui T, Yamagishi S. Vildagliptin inhibits oxidative stress and vascular damage in streptozotocin-induced diabetic rats. Int J Cardiol. 2012;158:171-3.
-
(2012)
Int J Cardiol
, vol.158
, pp. 171-173
-
-
Maeda, S.1
Matsui, T.2
Yamagishi, S.3
-
97
-
-
73349093759
-
Impact of glucagon-like peptide-1 on endothelial function
-
Sjöholm A. Impact of glucagon-like peptide-1 on endothelial function. Diabetes Obes Metab. 2009;11 Suppl 3:19-25.
-
(2009)
Diabetes Obes Metab
, vol.11
, pp. 19-25
-
-
Sjöholm, A.1
-
98
-
-
84920027998
-
Ratio of Serum Levels of AGEs to Soluble Form of RAGE Is A Predictor of Endothelial Function
-
Kajikawa M, Nakashima A, Fujimura N, Maruhashi T, Iwamoto Y, Iwamoto A et al. Ratio of Serum Levels of AGEs to Soluble Form of RAGE Is A Predictor of Endothelial Function. Diabetes Care 2014, doi: 10.2337/dc14-1435
-
(2014)
Diabetes Care
-
-
Kajikawa, M.1
Nakashima, A.2
Fujimura, N.3
Maruhashi, T.4
Iwamoto, Y.5
Iwamoto, A.6
-
99
-
-
34548679360
-
Pigment epithelium-derived factor (PEDF) prevents advanced glycation end products (AGEs)-elicited endothelial nitric oxide synthase (eNOS) reduction through its anti-oxidative properties
-
Yamagishi S, Ueda S, Matsui T, Nakamura K, Imaizumi T, Takeuchi M, et al. Pigment epithelium-derived factor (PEDF) prevents advanced glycation end products (AGEs)-elicited endothelial nitric oxide synthase (eNOS) reduction through its anti-oxidative properties. Protein Pept Lett. 2007;14:832-5.
-
(2007)
Protein Pept Lett
, vol.14
, pp. 832-835
-
-
Yamagishi, S.1
Ueda, S.2
Matsui, T.3
Nakamura, K.4
Imaizumi, T.5
Takeuchi, M.6
-
100
-
-
80052963329
-
Sitagliptin augments protective effects of GLP-1 against advanced glycation end product receptor axis in endothelial cells
-
Ishibashi Y, Matsui T, Takeuchi M, Yamagishi S. Sitagliptin augments protective effects of GLP-1 against advanced glycation end product receptor axis in endothelial cells. Horm Metab Res. 2011;43:731-4.
-
(2011)
Horm Metab Res
, vol.43
, pp. 731-734
-
-
Ishibashi, Y.1
Matsui, T.2
Takeuchi, M.3
Yamagishi, S.4
-
101
-
-
8544258807
-
Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease
-
Nyström T, Gutniak MK, Zhang Q, Zhang F, Holst JJ, Ahrén B, et al. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab. 2004;287:E1209-15.
-
(2004)
Am J Physiol Endocrinol Metab
, vol.287
, pp. E1209-E1215
-
-
Nyström, T.1
Gutniak, M.K.2
Zhang, Q.3
Zhang, F.4
Holst, J.J.5
Ahrén, B.6
-
102
-
-
84873737310
-
Serum levels of advanced glycation end products (AGEs) are independently correlated with circulating levels of dipeptidyl peptidase-4 (DPP-4) in humans
-
Tahara N, Yamagishi S, Takeuchi M, Tahara A, Kaifu K, Ueda S, et al. Serum levels of advanced glycation end products (AGEs) are independently correlated with circulating levels of dipeptidyl peptidase-4 (DPP-4) in humans. Clin Biochem. 2013;46:300-3.
-
(2013)
Clin Biochem
, vol.46
, pp. 300-303
-
-
Tahara, N.1
Yamagishi, S.2
Takeuchi, M.3
Tahara, A.4
Kaifu, K.5
Ueda, S.6
-
103
-
-
33947584619
-
Glucagon-like peptide 1 receptor expression in primary porcine proximal tubular cells
-
Schlatter P, Beglinger C, Drewe J, Gutmann H. Glucagon-like peptide 1 receptor expression in primary porcine proximal tubular cells. Regul Pept. 2007;141:120-8.
-
(2007)
Regul Pept
, vol.141
, pp. 120-128
-
-
Schlatter, P.1
Beglinger, C.2
Drewe, J.3
Gutmann, H.4
-
104
-
-
45449083028
-
Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are positively associated with circulating AGEs and soluble form of VCAM-1 in patients with type 2 diabetes
-
Nakamura K, Yamagishi S, Adachi H, Matsui T, Kurita-Nakamura Y, Takeuchi M, et al. Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are positively associated with circulating AGEs and soluble form of VCAM-1 in patients with type 2 diabetes. Microvasc Res. 2008;76:52-6.
-
(2008)
Microvasc Res
, vol.76
, pp. 52-56
-
-
Nakamura, K.1
Yamagishi, S.2
Adachi, H.3
Matsui, T.4
Kurita-Nakamura, Y.5
Takeuchi, M.6
-
105
-
-
23744514145
-
Plasma levels of AGE peptides in type 1 diabetic patients are associated with serum creatinine and not with albumin excretion rate: possible role of AGE peptide-associated endothelial dysfunction
-
Schalkwijk CG, Ter Wee PM, Stehouwer CD. Plasma levels of AGE peptides in type 1 diabetic patients are associated with serum creatinine and not with albumin excretion rate: possible role of AGE peptide-associated endothelial dysfunction. Ann N Y Acad Sci. 2005;1043:662-70.
-
(2005)
Ann N Y Acad Sci
, vol.1043
, pp. 662-670
-
-
Schalkwijk, C.G.1
Wee, P.M.2
Stehouwer, C.D.3
-
106
-
-
54049108485
-
A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane-bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10)
-
Raucci A, Cugusi S, Antonelli A, Barabino SM, Monti L, Bierhaus A, et al. A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane-bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10). FASEB J. 2008;22:3716-27.
-
(2008)
FASEB J
, vol.22
, pp. 3716-3727
-
-
Raucci, A.1
Cugusi, S.2
Antonelli, A.3
Barabino, S.M.4
Monti, L.5
Bierhaus, A.6
-
107
-
-
0031657655
-
Dipeptidyl peptidase IV from human serum: purification, characterization, and N-terminal amino acid sequence
-
Iwaki-Egawa S, Watanabe Y, Kikuya Y, Fujimoto Y. Dipeptidyl peptidase IV from human serum: purification, characterization, and N-terminal amino acid sequence. J Biochem. 1998;124:428-33.
-
(1998)
J Biochem
, vol.124
, pp. 428-433
-
-
Iwaki-Egawa, S.1
Watanabe, Y.2
Kikuya, Y.3
Fujimoto, Y.4
-
108
-
-
33846006173
-
The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes
-
Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368:1696-705.
-
(2006)
Lancet
, vol.368
, pp. 1696-1705
-
-
Drucker, D.J.1
Nauck, M.A.2
-
109
-
-
34248223285
-
Biology of incretins: GLP-1 and GIP
-
Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007;132:2131-57.
-
(2007)
Gastroenterology
, vol.132
, pp. 2131-2157
-
-
Baggio, L.L.1
Drucker, D.J.2
-
110
-
-
34247874561
-
Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes
-
Fonseca V, Schweizer A, Albrecht D, Baron MA, Chang I, Dejager S. Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia. 2007;50:1148-55.
-
(2007)
Diabetologia
, vol.50
, pp. 1148-1155
-
-
Fonseca, V.1
Schweizer, A.2
Albrecht, D.3
Baron, M.A.4
Chang, I.5
Dejager, S.6
-
111
-
-
84898920521
-
Diabetic cardiomyopathy: mechanisms and new treatment strategies targeting antioxidant signaling pathways
-
Huynh K, Bernardo BC, McMullen JR, Ritchie RH. Diabetic cardiomyopathy: mechanisms and new treatment strategies targeting antioxidant signaling pathways. Pharmacol Ther. 2014;142:375-415.
-
(2014)
Pharmacol Ther
, vol.142
, pp. 375-415
-
-
Huynh, K.1
Bernardo, B.C.2
McMullen, J.R.3
Ritchie, R.H.4
-
112
-
-
84896092380
-
Molecular mechanisms of diabetic cardiomyopathy
-
Bugger H, Abel ED. Molecular mechanisms of diabetic cardiomyopathy. Diabetologia. 2014;57:660-71.
-
(2014)
Diabetologia
, vol.57
, pp. 660-671
-
-
Bugger, H.1
Abel, E.D.2
-
113
-
-
84899119923
-
Advanced glycation end products: role in pathology of diabetic cardiomyopathy
-
Bodiga VL, Eda SR, Bodiga S. Advanced glycation end products: role in pathology of diabetic cardiomyopathy. Heart Fail Rev. 2014;19:49-63.
-
(2014)
Heart Fail Rev
, vol.19
, pp. 49-63
-
-
Bodiga, V.L.1
Eda, S.R.2
Bodiga, S.3
-
114
-
-
80055110463
-
Effects of DPP-4 inhibition on cardiac metabolism and function in mice
-
Lenski M, Kazakov A, Marx N, Böhm M, Laufs U. Effects of DPP-4 inhibition on cardiac metabolism and function in mice. J Mol Cell Cardiol. 2011;51:906-18.
-
(2011)
J Mol Cell Cardiol
, vol.51
, pp. 906-918
-
-
Lenski, M.1
Kazakov, A.2
Marx, N.3
Böhm, M.4
Laufs, U.5
-
115
-
-
84906503585
-
Exendin-4, a glucagon-like peptide-1 receptor agonist, inhibits hyperglycemia-induced apoptosis in myocytes by suppressing receptor for advanced glycation end products expression
-
Yi B, Hu X, Wen Z, Zhang T, Cai Y. Exendin-4, a glucagon-like peptide-1 receptor agonist, inhibits hyperglycemia-induced apoptosis in myocytes by suppressing receptor for advanced glycation end products expression. Exp Ther Med. 2014;8:1185-90.
-
(2014)
Exp Ther Med
, vol.8
, pp. 1185-1190
-
-
Yi, B.1
Hu, X.2
Wen, Z.3
Zhang, T.4
Cai, Y.5
-
116
-
-
84887202275
-
The dipeptidyl peptidase-4 inhibitor-sitagliptin modulates calcium dysregulation, inflammation, and PPARs in hypertensive cardiomyocytes
-
Lee TI, Kao YH, Chen YC, Huang JH, Hsu MI, Chen YJ. The dipeptidyl peptidase-4 inhibitor-sitagliptin modulates calcium dysregulation, inflammation, and PPARs in hypertensive cardiomyocytes. Int J Cardiol. 2013;168:5390-5.
-
(2013)
Int J Cardiol
, vol.168
, pp. 5390-5395
-
-
Lee, T.I.1
Kao, Y.H.2
Chen, Y.C.3
Huang, J.H.4
Hsu, M.I.5
Chen, Y.J.6
-
117
-
-
34548397224
-
Molecular mechanisms of diabetic nephropathy and its therapeutic intervention
-
Yamagishi S, Fukami K, Ueda S, Okuda S. Molecular mechanisms of diabetic nephropathy and its therapeutic intervention. Curr Drug Targets. 2007;8:952-9.
-
(2007)
Curr Drug Targets
, vol.8
, pp. 952-959
-
-
Yamagishi, S.1
Fukami, K.2
Ueda, S.3
Okuda, S.4
-
118
-
-
77955416176
-
The cardiorenal syndrome in diabetes mellitus
-
Karnib HH, Ziyadeh FN. The cardiorenal syndrome in diabetes mellitus. Diabetes Res Clin Pract. 2010;89:201-8.
-
(2010)
Diabetes Res Clin Pract
, vol.89
, pp. 201-208
-
-
Karnib, H.H.1
Ziyadeh, F.N.2
-
119
-
-
33846454303
-
Distinguishing diabetic nephropathy from other causes of glomerulosclerosis: an update
-
Alsaad KO, Herzenberg AM. Distinguishing diabetic nephropathy from other causes of glomerulosclerosis: an update. J Clin Pathol. 2007;60:18-26.
-
(2007)
J Clin Pathol
, vol.60
, pp. 18-26
-
-
Alsaad, K.O.1
Herzenberg, A.M.2
-
120
-
-
0027930904
-
Clinical and histological correlations of decline in renal function in diabetic patients with proteinuria
-
Taft JL, Nolan CJ, Yeung SP, Hewitson TD, Martin FI. Clinical and histological correlations of decline in renal function in diabetic patients with proteinuria. Diabetes. 1994;43:1046-51.
-
(1994)
Diabetes
, vol.43
, pp. 1046-1051
-
-
Taft, J.L.1
Nolan, C.J.2
Yeung, S.P.3
Hewitson, T.D.4
Martin, F.I.5
-
121
-
-
0025732119
-
The renal tubulointerstitium in diabetes mellitus
-
Ziyadeh FN, Goldfarb S. The renal tubulointerstitium in diabetes mellitus. Kidney Int. 1991;39:464-75.
-
(1991)
Kidney Int
, vol.39
, pp. 464-475
-
-
Ziyadeh, F.N.1
Goldfarb, S.2
-
122
-
-
0034947508
-
Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice
-
Yamamoto Y, Kato I, Doi T, Yonekura H, Ohashi S, Takeuchi M, et al. Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice. J Clin Invest. 2001;108:261-8.
-
(2001)
J Clin Invest
, vol.108
, pp. 261-268
-
-
Yamamoto, Y.1
Kato, I.2
Doi, T.3
Yonekura, H.4
Ohashi, S.5
Takeuchi, M.6
-
123
-
-
0037377697
-
RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy
-
Wendt TM, Tanji N, Guo J, Kislinger TR, Qu W, Lu Y, et al. RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am J Pathol. 2003;162:1123-37.
-
(2003)
Am J Pathol
, vol.162
, pp. 1123-1137
-
-
Wendt, T.M.1
Tanji, N.2
Guo, J.3
Kislinger, T.R.4
Qu, W.5
Lu, Y.6
-
124
-
-
77955375901
-
Deletion of the receptor for advanced glycation end products reduces glomerulosclerosis and preserves renal function in the diabetic OVE26 mouse
-
Reiniger N, Lau K, McCalla D, Eby B, Cheng B, Lu Y, et al. Deletion of the receptor for advanced glycation end products reduces glomerulosclerosis and preserves renal function in the diabetic OVE26 mouse. Diabetes. 2010;59:2043-54.
-
(2010)
Diabetes
, vol.59
, pp. 2043-2054
-
-
Reiniger, N.1
Lau, K.2
McCalla, D.3
Eby, B.4
Cheng, B.5
Lu, Y.6
-
125
-
-
0037036345
-
Advanced glycation end product-induced apoptosis and overexpression of vascular endothelial growth factor and monocyte chemoattractant protein-1 in human-cultured mesangial cells
-
Yamagishi S, Inagaki Y, Okamoto T, Amano S, Koga K, Takeuchi M, et al. Advanced glycation end product-induced apoptosis and overexpression of vascular endothelial growth factor and monocyte chemoattractant protein-1 in human-cultured mesangial cells. J Biol Chem. 2002;277:20309-15.
-
(2002)
J Biol Chem
, vol.277
, pp. 20309-20315
-
-
Yamagishi, S.1
Inagaki, Y.2
Okamoto, T.3
Amano, S.4
Koga, K.5
Takeuchi, M.6
-
127
-
-
0022137599
-
Contractile properties of cultured glomerular mesangial cells
-
Kreisberg JI, Venkatachalam M, Troyer D. Contractile properties of cultured glomerular mesangial cells. Am J Physiol. 1985;249:F457-63.
-
(1985)
Am J Physiol
, vol.249
, pp. F457-F463
-
-
Kreisberg, J.I.1
Venkatachalam, M.2
Troyer, D.3
-
128
-
-
0023550339
-
The glomerular mesangial cell: an expanding role for a specialized pericyte
-
Schlondorff D. The glomerular mesangial cell: an expanding role for a specialized pericyte. FASEB J. 1987;1:272-81.
-
(1987)
FASEB J
, vol.1
, pp. 272-281
-
-
Schlondorff, D.1
-
129
-
-
0035034655
-
Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes
-
De Vriese AS, Tilton RG, Elger M, Stephan CC, Kriz W, Lameire NH. Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes. J Am Soc Nephrol. 2001;12:993-1000.
-
(2001)
J Am Soc Nephrol
, vol.12
, pp. 993-1000
-
-
Vriese, A.S.1
Tilton, R.G.2
Elger, M.3
Stephan, C.C.4
Kriz, W.5
Lameire, N.H.6
-
130
-
-
0033865561
-
Possible relationship of monocyte chemoattractant protein-1 with diabetic nephropathy
-
Banba N, Nakamura T, Matsumura M, Kuroda H, Hattori Y, Kasai K. Possible relationship of monocyte chemoattractant protein-1 with diabetic nephropathy. Kidney Int. 2000;58:684-90.
-
(2000)
Kidney Int
, vol.58
, pp. 684-690
-
-
Banba, N.1
Nakamura, T.2
Matsumura, M.3
Kuroda, H.4
Hattori, Y.5
Kasai, K.6
-
131
-
-
0036781581
-
Circulating monocyte chemoattractant protein-1 and early development of nephropathy in type 1 diabetes
-
Chiarelli F, Cipollone F, Mohn A, Marini M, Iezzi A, Fazia M, et al. Circulating monocyte chemoattractant protein-1 and early development of nephropathy in type 1 diabetes. Diabetes Care. 2002;25:1829-34.
-
(2002)
Diabetes Care
, vol.25
, pp. 1829-1834
-
-
Chiarelli, F.1
Cipollone, F.2
Mohn, A.3
Marini, M.4
Iezzi, A.5
Fazia, M.6
-
132
-
-
70349974064
-
Intensive insulin therapy decreases urinary MCP-1 and ICAN-1 excretions in incipient diabetic nephropathy
-
Ye SD, Zheng M, Zhao LL, Qian Y, Yao XM, Ren A, et al. Intensive insulin therapy decreases urinary MCP-1 and ICAN-1 excretions in incipient diabetic nephropathy. Eur J Clin Invest. 2009;39:980-5.
-
(2009)
Eur J Clin Invest
, vol.39
, pp. 980-985
-
-
Ye, S.D.1
Zheng, M.2
Zhao, L.L.3
Qian, Y.4
Yao, X.M.5
Ren, A.6
-
133
-
-
30944456936
-
Monocyte chemoattractant protein-1 promotes the development of diabetic renal injury in streptozotocin-treated mice
-
Chow FY, Nikolic-Paterson DJ, Ozols E, Atkins RC, Rollin BJ, Tesch GH. Monocyte chemoattractant protein-1 promotes the development of diabetic renal injury in streptozotocin-treated mice. Kidney Int. 2006;69:73-80.
-
(2006)
Kidney Int
, vol.69
, pp. 73-80
-
-
Chow, F.Y.1
Nikolic-Paterson, D.J.2
Ozols, E.3
Atkins, R.C.4
Rollin, B.J.5
Tesch, G.H.6
-
134
-
-
80051800781
-
Glucagon-like peptide-1 suppresses advanced glycation end product-induced monocyte chemoattractant protein-1 expression in mesangial cells by reducing advanced glycation end product receptor level
-
Ishibashi Y, Nishino Y, Matsui T, Takeuchi M, Yamagishi SI. Glucagon-like peptide-1 suppresses advanced glycation end product-induced monocyte chemoattractant protein-1 expression in mesangial cells by reducing advanced glycation end product receptor level. Metabolism. 2011;60:1271-7.
-
(2011)
Metabolism
, vol.60
, pp. 1271-1277
-
-
Ishibashi, Y.1
Nishino, Y.2
Matsui, T.3
Takeuchi, M.4
Yamagishi, S.I.5
-
135
-
-
84871309097
-
Glucagon-like peptide-1 receptor agonist inhibits asymmetric dimethylarginine generation in the kidney of streptozotocin-induced diabetic rats by blocking advanced glycation end product-induced protein arginine methyltranferase-1 expression
-
Ojima A, Ishibashi Y, Matsui T, Maeda S, Nishino Y, Takeuchi M, et al. Glucagon-like peptide-1 receptor agonist inhibits asymmetric dimethylarginine generation in the kidney of streptozotocin-induced diabetic rats by blocking advanced glycation end product-induced protein arginine methyltranferase-1 expression. Am J Pathol. 2013;182:132-41.
-
(2013)
Am J Pathol
, vol.182
, pp. 132-141
-
-
Ojima, A.1
Ishibashi, Y.2
Matsui, T.3
Maeda, S.4
Nishino, Y.5
Takeuchi, M.6
-
136
-
-
38349048006
-
Nitric oxide deficiency in chronic kidney disease
-
Baylis C. Nitric oxide deficiency in chronic kidney disease. Am J Physiol Renal Physiol. 2008;294:F1-9.
-
(2008)
Am J Physiol Renal Physiol
, vol.294
, pp. F1-F9
-
-
Baylis, C.1
-
137
-
-
79960014508
-
Nitric oxide, a janus-faced therapeutic target for diabetic microangiopathy-Friend or foe?
-
Yamagishi S, Matsui T. Nitric oxide, a janus-faced therapeutic target for diabetic microangiopathy-Friend or foe? Pharmacol Res. 2011;64:187-94.
-
(2011)
Pharmacol Res
, vol.64
, pp. 187-194
-
-
Yamagishi, S.1
Matsui, T.2
-
138
-
-
57349128859
-
Role of asymmetric dimethylarginine (ADMA) in diabetic vascular complications
-
Yamagishi S, Ueda S, Nakamura K, Matsui T, Okuda S. Role of asymmetric dimethylarginine (ADMA) in diabetic vascular complications. Curr Pharm Des. 2008;14:2613-8.
-
(2008)
Curr Pharm Des
, vol.14
, pp. 2613-2618
-
-
Yamagishi, S.1
Ueda, S.2
Nakamura, K.3
Matsui, T.4
Okuda, S.5
-
139
-
-
0030588667
-
The L-arginine-nitric oxide pathway: role in atherosclerosis and therapeutic implications
-
Böger RH, Bode-Böger SM, Frölich JC. The L-arginine-nitric oxide pathway: role in atherosclerosis and therapeutic implications. Atherosclerosis. 1996;127:1-11.
-
(1996)
Atherosclerosis
, vol.127
, pp. 1-11
-
-
Böger, R.H.1
Bode-Böger, S.M.2
Frölich, J.C.3
-
140
-
-
1442299806
-
Elevated plasma asymmetric dimethylarginine as a marker of cardiovascular morbidity in early diabetic nephropathy in type 1 diabetes
-
Tarnow L, Hovind P, Teerlink T, Stehouwer CD, Parving HH. Elevated plasma asymmetric dimethylarginine as a marker of cardiovascular morbidity in early diabetic nephropathy in type 1 diabetes. Diabetes Care. 2004;27:765-9.
-
(2004)
Diabetes Care
, vol.27
, pp. 765-769
-
-
Tarnow, L.1
Hovind, P.2
Teerlink, T.3
Stehouwer, C.D.4
Parving, H.H.5
-
141
-
-
70449715636
-
Positive association of serum levels of advanced glycation end products and high mobility group box-1 with asymmetric dimethylarginine in nondiabetic chronic kidney disease patients
-
Nakamura T, Sato E, Fujiwara N, Kawagoe Y, Ueda Y, Suzuki T, et al. Positive association of serum levels of advanced glycation end products and high mobility group box-1 with asymmetric dimethylarginine in nondiabetic chronic kidney disease patients. Metabolism. 2009;58:1624-8.
-
(2009)
Metabolism
, vol.58
, pp. 1624-1628
-
-
Nakamura, T.1
Sato, E.2
Fujiwara, N.3
Kawagoe, Y.4
Ueda, Y.5
Suzuki, T.6
-
142
-
-
84882322069
-
Involvement of advanced glycation end product-induced asymmetric dimethylarginine generation in endothelial dysfunction
-
Ando R, Ueda S, Yamagishi S, Miyazaki H, Kaida Y, Kaifu K, et al. Involvement of advanced glycation end product-induced asymmetric dimethylarginine generation in endothelial dysfunction. Diab Vasc Dis Res. 2013;10:436-41.
-
(2013)
Diab Vasc Dis Res
, vol.10
, pp. 436-441
-
-
Ando, R.1
Ueda, S.2
Yamagishi, S.3
Miyazaki, H.4
Kaida, Y.5
Kaifu, K.6
-
143
-
-
34547843478
-
Potential utility of telmisartan, an angiotensin II type 1 receptor blocker with peroxisome proliferator-activated receptor-gamma (PPAR-gamma)-modulating activity for the treatment of cardiometabolic disorders
-
Yamagishi S, Nakamura K, Matsui T. Potential utility of telmisartan, an angiotensin II type 1 receptor blocker with peroxisome proliferator-activated receptor-gamma (PPAR-gamma)-modulating activity for the treatment of cardiometabolic disorders. Curr Mol Med. 2007;7:463-9.
-
(2007)
Curr Mol Med
, vol.7
, pp. 463-469
-
-
Yamagishi, S.1
Nakamura, K.2
Matsui, T.3
-
144
-
-
84901980075
-
Olmesartan blocks advanced glycation end products-induced vcam-1 gene expression in mesangial cells by restoring Angiotensin-converting enzyme 2 level
-
Ishibashi Y, Matsui T, Yamagishi S. Olmesartan blocks advanced glycation end products-induced vcam-1 gene expression in mesangial cells by restoring Angiotensin-converting enzyme 2 level. Horm Metab Res. 2014;46:379-83.
-
(2014)
Horm Metab Res
, vol.46
, pp. 379-383
-
-
Ishibashi, Y.1
Matsui, T.2
Yamagishi, S.3
-
145
-
-
84868144237
-
Glucagon-like peptide-1 inhibits angiotensin II-induced mesangial cell damage via protein kinase A
-
Ishibashi Y, Matsui T, Ojima A, Nishino Y, Nakashima S, Maeda S, et al. Glucagon-like peptide-1 inhibits angiotensin II-induced mesangial cell damage via protein kinase A. Microvasc Res. 2012;84:395-8.
-
(2012)
Microvasc Res
, vol.84
, pp. 395-398
-
-
Ishibashi, Y.1
Matsui, T.2
Ojima, A.3
Nishino, Y.4
Nakashima, S.5
Maeda, S.6
-
146
-
-
21344451403
-
Hyperglycaemia increases dipeptidyl peptidase IV activity in diabetes mellitus
-
Mannucci E, Pala L, Ciani S, Bardini G, Pezzatini A, Sposato I, et al. Hyperglycaemia increases dipeptidyl peptidase IV activity in diabetes mellitus. Diabetologia. 2005;48:1168-72.
-
(2005)
Diabetologia
, vol.48
, pp. 1168-1172
-
-
Mannucci, E.1
Pala, L.2
Ciani, S.3
Bardini, G.4
Pezzatini, A.5
Sposato, I.6
-
147
-
-
84929469873
-
Linagliptin blocks renal damage in type 1 diabetic rats by suppressing advanced glycation end products-receptor axis
-
Nakashima S, Matsui T, Takeuchi M, Yamagishi SI. Linagliptin blocks renal damage in type 1 diabetic rats by suppressing advanced glycation end products-receptor axis. Horm Metab Res. 2014;46:717-21.
-
(2014)
Horm Metab Res
, vol.46
, pp. 717-721
-
-
Nakashima, S.1
Matsui, T.2
Takeuchi, M.3
Yamagishi, S.I.4
-
148
-
-
84878664709
-
A diabetes treatment strategy to reduce the risk of cardiovascular events; Clinical benefits and potential of linagliptin
-
Morishita R, Yamagishi S. A diabetes treatment strategy to reduce the risk of cardiovascular events; Clinical benefits and potential of linagliptin. Immun Endoc Metab Agents Med Chem. 2013;13:81-8.
-
(2013)
Immun Endoc Metab Agents Med Chem
, vol.13
, pp. 81-88
-
-
Morishita, R.1
Yamagishi, S.2
-
149
-
-
84922404737
-
Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor, decreases serum uric acid levels in type 2 diabetic patients partly by suppressing xanthine oxidase activity
-
Yamagishi S, Ishibashi Y, Ojima A, Sugiura T, Matsui T. Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor, decreases serum uric acid levels in type 2 diabetic patients partly by suppressing xanthine oxidase activity. Int J Cardiol. 2014;176:550-2.
-
(2014)
Int J Cardiol
, vol.176
, pp. 550-552
-
-
Yamagishi, S.1
Ishibashi, Y.2
Ojima, A.3
Sugiura, T.4
Matsui, T.5
-
150
-
-
84883560410
-
Efficacy of alogliptin, a dipeptidyl peptidase-4 inhibitor, on glucose parameters, the activity of the advanced glycation end product (AGE) - receptor for AGE (RAGE) axis and albuminuria in Japanese type 2 diabetes
-
Sakata K, Hayakawa M, Yano Y, Tamaki N, Yokota N, Eto T, et al. Efficacy of alogliptin, a dipeptidyl peptidase-4 inhibitor, on glucose parameters, the activity of the advanced glycation end product (AGE) - receptor for AGE (RAGE) axis and albuminuria in Japanese type 2 diabetes. Diabetes Metab Res Rev. 2013;29:624-30.
-
(2013)
Diabetes Metab Res Rev
, vol.29
, pp. 624-630
-
-
Sakata, K.1
Hayakawa, M.2
Yano, Y.3
Tamaki, N.4
Yokota, N.5
Eto, T.6
-
151
-
-
84888212579
-
Beneficial effects of vildagliptin on retinal injury in obese type 2 diabetic rats
-
Maeda S, Yamagishi S, Matsui T, Nakashima S, Ojima A, Maeda S, et al. Beneficial effects of vildagliptin on retinal injury in obese type 2 diabetic rats. Ophthalmic Res. 2013;50:221-6.
-
(2013)
Ophthalmic Res
, vol.50
, pp. 221-226
-
-
Maeda, S.1
Yamagishi, S.2
Matsui, T.3
Nakashima, S.4
Ojima, A.5
Maeda, S.6
-
152
-
-
84886451568
-
Exendin-4 and GLP-1 decreases induced expression of ICAM-1, VCAM-1 and RAGE in human retinal pigment epithelial cells
-
Dorecka M, Siemianowicz K, Francuz T, Garczorz W, Chyra A, Klych A, et al. Exendin-4 and GLP-1 decreases induced expression of ICAM-1, VCAM-1 and RAGE in human retinal pigment epithelial cells. Pharmacol Rep. 2013;65:884-90.
-
(2013)
Pharmacol Rep
, vol.65
, pp. 884-890
-
-
Dorecka, M.1
Siemianowicz, K.2
Francuz, T.3
Garczorz, W.4
Chyra, A.5
Klych, A.6
-
153
-
-
84908199242
-
The effects of dipeptidyl peptidase-4 inhibition on microvascular diabetes complications
-
Avogaro A, Fadini GP. The effects of dipeptidyl peptidase-4 inhibition on microvascular diabetes complications. Diabetes Care. 2014;37:2884-94.
-
(2014)
Diabetes Care
, vol.37
, pp. 2884-2894
-
-
Avogaro, A.1
Fadini, G.P.2
-
154
-
-
83955161115
-
A novel long acting DPP-IV inhibitor PKF-275-055 stimulates β-cell proliferation resulting in improved glucose homeostasis in diabetic rats
-
Akarte AS, Srinivasan BP, Gandhi S. A novel long acting DPP-IV inhibitor PKF-275-055 stimulates β-cell proliferation resulting in improved glucose homeostasis in diabetic rats. Biochem Pharmacol. 2012;83:241-52.
-
(2012)
Biochem Pharmacol
, vol.83
, pp. 241-252
-
-
Akarte, A.S.1
Srinivasan, B.P.2
Gandhi, S.3
-
155
-
-
77955273235
-
Glucagon-like peptide-1 counteracts the detrimental effects of Advanced Glycation End-Products in the pancreatic beta cell line HIT-T 15
-
Puddu A, Storace D, Durante A, Odetti P, Viviani GL. Glucagon-like peptide-1 counteracts the detrimental effects of Advanced Glycation End-Products in the pancreatic beta cell line HIT-T 15. Biochem Biophys Res Commun. 2010;398:462-6.
-
(2010)
Biochem Biophys Res Commun
, vol.398
, pp. 462-466
-
-
Puddu, A.1
Storace, D.2
Durante, A.3
Odetti, P.4
Viviani, G.L.5
-
156
-
-
84877979074
-
Glucagon-like peptide-1 triggers protective pathways in pancreatic beta-cells exposed to glycated serum
-
Puddu A, Sanguineti R, Durante A, Nencioni A, Mach F, Montecucco F, et al. Glucagon-like peptide-1 triggers protective pathways in pancreatic beta-cells exposed to glycated serum. Mediators Inflamm. 2013;2013:317120.
-
(2013)
Mediators Inflamm
, vol.2013
, pp. 317120
-
-
Puddu, A.1
Sanguineti, R.2
Durante, A.3
Nencioni, A.4
Mach, F.5
Montecucco, F.6
Viviani, G.L.7
-
157
-
-
84873403513
-
An emerging role of glucagon-like peptide-1 in preventing advanced-glycation-end-product-mediated damages in diabetes
-
Puddu A, Mach F, Nencioni A, Viviani GL, Montecucco F. An emerging role of glucagon-like peptide-1 in preventing advanced-glycation-end-product-mediated damages in diabetes. Mediators Inflamm. 2013;2013:591056.
-
(2013)
Mediators Inflamm.
, vol.2013
, pp. 591056
-
-
Puddu, A.1
Mach, F.2
Nencioni, A.3
Viviani, G.L.4
Montecucco, F.5
|